Palmitoyl Tripeptide-1 vs Humanin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Palmitoyl Tripeptide-1
Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide that stimulates collagen production. It's one of two peptides in the Matrixyl 3000 complex, working synergistically with Palmitoyl Tetrapeptide-7.
Full details →Humanin
Humanin is a mitochondrial-derived peptide with potent cytoprotective effects. Discovered in 2001, it has shown promise in protecting against age-related diseases including Alzheimer's, cardiovascular disease, and diabetes.
Full details →Side-by-Side Comparison
| Aspect | Palmitoyl Tripeptide-1 | Humanin |
|---|---|---|
| Mechanism | Mimics the skin's own mechanism for producing collagen by acting as a messenger peptide that signals fibroblasts to produce more collagen and other extracellular matrix components. | Binds to IGFBP-3 and BAX, inhibiting apoptosis. Activates STAT3 signaling and enhances cellular survival under stress. Protects mitochondrial function and reduces oxidative stress. |
| Typical Dosage | Topical: Typically 2-4% in serums, often combined with Palmitoyl Tetrapeptide-7 as Matrixyl 3000. | Research protocols vary widely. Studies have used doses from micrograms to milligrams depending on the analog and route. HNG (S14G-Humanin) is a more potent analog. |
| Administration | Topical application 1-2 times daily. The palmitoyl group enhances skin penetration compared to non-lipidated versions. | Subcutaneous or intraperitoneal injection in research. Various analogs exist with different potencies and stabilities. |
| Side Effects | Very well-tolerated. Suitable for most skin types including sensitive skin. | Limited human data. Generally well-tolerated in animal studies. May affect glucose metabolism. |
| Best For |
What They Have in Common
Both Palmitoyl Tripeptide-1 and Humanin are commonly used for: